Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May 1;211(9):1373-5.
doi: 10.1093/infdis/jiu648. Epub 2014 Nov 24.

Raising expectations for subunit vaccine

John T Schiller  1 , Douglas R Lowy  1
Affiliations
Review

Raising expectations for subunit vaccine

John T Schiller et al. J Infect Dis. .

Abstract

Multidose regimens are recommended for all prophylactic subunit vaccines. Recent findings from clinical trials of an human papillomavirus virus-like particle vaccine suggest that it may be possible to develop effective single-dose subunit vaccines. The broad implications of these findings are discussed, and the importance of antigen structure and adjuvant in achieving this goal is considered. In conclusion, we argue for the inclusion of single-dose arms in future trials of vaccines, especially if they are based on induction of antibodies by virus-like displayed antigens.

Keywords: HBV; HPV; antibody; memory B cell; plasma cell; prophylactic vaccine; virus-like particle.

PubMed Disclaimer

Comment in

  • Single-Dose Vaccines.
    Nalin DR. Nalin DR. J Infect Dis. 2015 Dec 15;212(12):2021. doi: 10.1093/infdis/jiv393. Epub 2015 Aug 12. J Infect Dis. 2015. PMID: 26272933 No abstract available.
  • Reply to Nalin.
    Schiller JT, Lowy DR. Schiller JT, et al. J Infect Dis. 2015 Dec 15;212(12):2021-2. doi: 10.1093/infdis/jiv394. Epub 2015 Aug 12. J Infect Dis. 2015. PMID: 26272934 Free PMC article. No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11(4 suppl):S5–11. - PMC - PubMed
    1. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(suppl 5):F123–38. - PMC - PubMed
    1. Roteli-Martins C, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8:390–7. - PubMed
    1. Amanna IJ, Slifka MK. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology 2011; 411:206–15. - PMC - PubMed
    1. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357:1903–15. - PubMed

Publication types

MeSH terms